Abstract
High-dose chemotherapy and stem cell rescue is increasingly being delivered in the outpatient setting. Such intensive outpatient management programs have reduced the total hospital length of stay without compromising clinical outcomes. However, a detailed financial analysis of outpatient programs has not been performed. These data are the results of a prospective study of 94 patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant in one of three settings: traditional inpatient, partial outpatient, total outpatient. Patients were allowed to choose their own treatment setting based upon the availability of a caregiver and personal preference. Total hospital length of stay and the actual cost and charges for each patient were monitored prospectively. The patients in the three groups were well balanced with regard to age and functional status prior to high-dose chemotherapy. The average length of stay was reduced from 17.3 to 8.2 to 2.7 days in the three different treatment settings (P < 0.01). mean procedure costs were reduced from $39.7 thousand (us dollars) to $36.2 thousand to $29.4 thousand in the three treatment settings (P < 0.029). no differences in toxicity or overall response to therapy was noted. high-dose chemotherapy and stem cell rescue can be safely administered in the outpatient setting and results in significant cost savings.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Meisenberg, B., Ferran, K., Hollenbach, K. et al. Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant 21, 927–932 (1998). https://doi.org/10.1038/sj.bmt.1701191
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701191
Keywords
This article is cited by
-
Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial
Advances in Therapy (2023)
-
Caregiver availability and patient access to hematopoietic cell transplantation: social worker perspectives inform practice
Supportive Care in Cancer (2019)
-
High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting
BMC Cancer (2017)
-
Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma
Bone Marrow Transplantation (2016)
-
Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma
Bone Marrow Transplantation (2015)